Skip to content
White_Call

05/11/2024 – We are currently experiencing issues with our phonelines. We apologise for any inconvenience.  Until further notice, please contact us using the patient contact form https://www.sciensus.com/patient-enquiry/  

 

Boys playing football

Leveraging Early Access Programs and Real-World Data for commercial success

Andrew Cummins

By Andrew Cummins

Director of Expanded Access Programs

Your essential guide to Early Access Programs and Real-World Data in Europe

Discover the key considerations, steps, and strategies needed to establish a successful expanded access program (EAP) in Europe.

This guide is derived from a comprehensive webinar featuring insights from three industry experts:
• Andrew Cummins, Director of Expanded Access Programs at Sciensus
• Mathieu Loiseau, Director of Rare Clinical Services at Sciensus
• Sara Radenovic, Director of Managed Access Programs at GSK

What’s inside?

This whitepaper gives in-depth advice and guidance for biotechs on how to design and establish a successful EAP in Europe.

Learn more about:

  • When and why companies turn to EAPs and how you can ensure the success of your EAP
  • The importance of real-world data for rare and orphan medicines and how to collect it as part of an EAP
  • What to do if your company doesn’t already have a European presence